By promoting the growth of beneficial bacteria and supporting short-chain fatty acid (SCFA) production, GLP-Balance helps create a favorable environment for satiety, nutrient absorption, and weight management.*
in the LEADER, REWIND, EXSCEL, ELIXA and SUSTAIN-6 trials were no significant difference in HF hospitalization between GLP-1 receptor agonist and placebo group (3744, 66)
David Macklin's weight management practice in Toronto, the name Ozempic is mentioned almost daily in appointments
If nutritional markers are not already included at baseline and follow-up intervals, consider adding them
Our providers consider the full clinical picture, so your treatment targets more than the number on the scale